CY1118181T1 - Αναβραζοντα δισκια για χρηση σε εισπνοες - Google Patents

Αναβραζοντα δισκια για χρηση σε εισπνοες

Info

Publication number
CY1118181T1
CY1118181T1 CY20161101120T CY161101120T CY1118181T1 CY 1118181 T1 CY1118181 T1 CY 1118181T1 CY 20161101120 T CY20161101120 T CY 20161101120T CY 161101120 T CY161101120 T CY 161101120T CY 1118181 T1 CY1118181 T1 CY 1118181T1
Authority
CY
Cyprus
Prior art keywords
suspension
restoreable
discs
drug
particle size
Prior art date
Application number
CY20161101120T
Other languages
English (en)
Inventor
Marco Gentile
Marco Cantarini
Original Assignee
Dompé Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompé Farmaceutici S.P.A. filed Critical Dompé Farmaceutici S.P.A.
Publication of CY1118181T1 publication Critical patent/CY1118181T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται στη χρήση αναβραζόντων δισκίων τα οποία περιέχουν αδιάλυτα δραστικά συστατικά για την παρασκευή εναιωρήματος για χρήση σε εισπνοές τα οποία διατηρούν το πρωτογενές μέγεθος σωματιδίων της φαρμακευτικής ουσίας. Τα δισκία διαλύονται στο διάλυμα έως ότου σχηματιστεί ένα εναιώρημα. Το εναιώρημα διατηρεί την αρχική κατανομή μεγέθους σωματιδίων της φαρμακευτικής ουσίας, εξασφαλίζοντας την επίτευξη του θεραπευτικού παραθύρου του εισπνεόμενου κλάσματος.
CY20161101120T 2007-06-22 2016-11-03 Αναβραζοντα δισκια για χρηση σε εισπνοες CY1118181T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07110896 2007-06-22
PCT/EP2008/004993 WO2009000473A2 (en) 2007-06-22 2008-06-20 Effervescent tablets for inhalatory use
EP08784529.3A EP2170348B1 (en) 2007-06-22 2008-06-20 Effervescent tablets for inhalatory use

Publications (1)

Publication Number Publication Date
CY1118181T1 true CY1118181T1 (el) 2017-06-28

Family

ID=40186078

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161101120T CY1118181T1 (el) 2007-06-22 2016-11-03 Αναβραζοντα δισκια για χρηση σε εισπνοες

Country Status (13)

Country Link
EP (1) EP2170348B1 (el)
BR (1) BRPI0814716A2 (el)
CY (1) CY1118181T1 (el)
DK (1) DK2170348T3 (el)
EA (1) EA021148B1 (el)
ES (1) ES2601860T3 (el)
HR (1) HRP20161388T1 (el)
HU (1) HUE030605T2 (el)
LT (1) LT2170348T (el)
PL (1) PL2170348T3 (el)
PT (1) PT2170348T (el)
SI (1) SI2170348T1 (el)
WO (1) WO2009000473A2 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1921919B1 (en) 2005-07-14 2012-04-04 Lithera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
RS51649B (en) * 2008-07-21 2011-10-31 Dr. Falk Pharma Gmbh. PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF THE UPPER DIGESTIVE TRACT
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
BR112012017556A2 (pt) * 2010-01-15 2016-08-16 Lithera Inc formulações de torta liofilizada
GB2485885B (en) 2010-11-24 2015-06-17 Neothetics Inc Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1438019A1 (en) * 2001-10-24 2004-07-21 PARI GmbH Spezialisten für effektive Inhalation Kit for the preparation of a pharmaceutical composition
ITMI20020808A1 (it) * 2002-04-17 2003-10-17 Chiesi Farma Spa Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
US20040045546A1 (en) * 2002-09-05 2004-03-11 Peirce Management, Llc Pharmaceutical delivery system for oral inhalation through nebulization consisting of inert substrate impregnated with substance (S) to be solubilized or suspended prior to use
ITFI20030194A1 (it) * 2003-07-17 2005-01-18 Menarini Int Operations Lu Sa Composizione farmaceutiche effervescenti contenenti

Also Published As

Publication number Publication date
PL2170348T3 (pl) 2017-01-31
EA021148B1 (ru) 2015-04-30
BRPI0814716A2 (pt) 2015-02-24
PT2170348T (pt) 2016-11-02
SI2170348T1 (sl) 2016-12-30
HRP20161388T1 (hr) 2016-12-02
ES2601860T3 (es) 2017-02-16
DK2170348T3 (en) 2016-11-07
HUE030605T2 (hu) 2017-05-29
WO2009000473A3 (en) 2009-07-30
EP2170348A2 (en) 2010-04-07
LT2170348T (lt) 2016-11-25
EA200971113A1 (ru) 2010-04-30
EP2170348B1 (en) 2016-08-10
WO2009000473A2 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
CY1118181T1 (el) Αναβραζοντα δισκια για χρηση σε εισπνοες
CY1114215T1 (el) Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
MX2012012438A (es) Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
EA201590449A1 (ru) Перорально вводимая лекарственная композиция
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
MX2011008634A (es) Derivados de aminotetralina composiciones farmaceuticas que los contienen y su uso en terapia.
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
UA106634C2 (uk) Тверда фармацевтична дозована форма
BR112015018168A2 (pt) inibidores de rock suaves
TR200900878A2 (tr) Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
WO2013147649A3 (ru) ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ
EA201590697A1 (ru) Производные кетамина
PH12015500823A1 (en) Modified release formulations for oprozomib
MX340188B (es) Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
CY1121973T1 (el) Θεραπεια φαρμακευτικα ανθεκτικου καρκινου η οποια στοχευει καρκινικα βλαστοκυτταρα
EA201290694A1 (ru) Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназы
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy